Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||nasopharynx carcinoma||not applicable||Camrelizumab + Cisplatin + Gemcitabine||Phase I||Actionable||In a Phase I trial, combination of Camrelizumab (SHR-1210), Gemzar (gemcitabine), and Platinol (cisplatin) demonstrated safety and preliminary anti-tumor activity in patients with treatment-naive nasopharyngeal carcinoma, resulted in an objective response rate of 91% (20/22, 1 complete response and 19 partial responses) and a disease control of 100% (22/22, stable disease or better (PMID: 30213452; NCT03121716).||30213452|